Sasso E, Paciello R, D’Auria F, Riccio G, Froechlich G, Cortese R, et al. One-step recovery of scFv clones from high-throughput sequencing-based screening of phage display libraries challenged to cells expressing native claudin-1. Biomed Res Int. 2015;2015:703213.
Article PubMed PubMed Central Google Scholar
Zambrano N, Froechlich G, Lazarevic D, Passariello M, Nicosia A, De Lorenzo C, et al. High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand. Cancers. 2022;14:1325.
Article CAS PubMed PubMed Central Google Scholar
Esposito MV, Minopoli G, Esposito L, D’Argenio V, Di Maggio F, Sasso E, et al. A functional analysis of the unclassified Pro2767Ser BRCA2 variant reveals its potential pathogenicity that acts by hampering DNA binding and homology-mediated DNA repair. Cancers. 2019;11:1454.
Article CAS PubMed PubMed Central Google Scholar
Barsi S, Szalai B. Modeling in systems biology: causal understanding before prediction? Patterns. 2021;2:100280.
Article PubMed PubMed Central Google Scholar
Chen R, Snyder M. Systems biology: personalized medicine for the future? Curr Opin Pharmacol. 2012;12:623–8.
Article CAS PubMed PubMed Central Google Scholar
Passariello M, Vetrei C, Sasso E, Froechlich G, Gentile C, D’Alise AM, et al. Isolation of two novel human anti-CTLA-4 mAbs with intriguing biological properties on tumor and NK cells. Cancers. 2020;12:2204.
Article CAS PubMed PubMed Central Google Scholar
Guhathakurta D, Sheikh NA, Meagher TC, Letarte S, Trager JB. Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. Expert Rev Clin Pharmacol. 2013;6:387–401.
Article CAS PubMed Google Scholar
D’Alise AM, Nocchi L, Garzia I, Seclì L, Infante L, Troise F, et al. Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer. Front Immunol. 2023;14:1156714.
Article PubMed PubMed Central Google Scholar
Lembo RR, Manna L, Froechlich G, Sasso E, Passariello M, De Lorenzo C. New insights on the role of anti-PD-L1 and anti-CTLA-4 mAbs on different lymphocytes subpopulations in TNBC. Cancers. 2022;14:5289.
Article CAS PubMed PubMed Central Google Scholar
Gentile C, Finizio A, Froechlich G, D’Alise AM, Cotugno G, Amiranda S, et al. Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance. Int J Mol Sci. 2021;22:13521.
Article CAS PubMed PubMed Central Google Scholar
Froechlich G, Caiazza C, Gentile C, D’Alise AM, De Lucia M, Langone F, et al. Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of herpes simplex oncolytic virus. Cancers. 2020;12:3407.
Article CAS PubMed PubMed Central Google Scholar
Hewitt SL, Bai A, Bailey D, Ichikawa K, Zielinski J, Karp R, et al. Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs. Sci Transl Med. 2019;11:eaat9143.
Article CAS PubMed Google Scholar
Gelzo M, Scialò F, Cacciapuoti S, Pinchera B, De Rosa A, Cernera G, et al. Inducible nitric oxide synthase (iNOS): why a different production in COVID-19 patients of the two waves? Viruses. 2022;14:534.
Article CAS PubMed PubMed Central Google Scholar
Guo ZS, Liu Z, Kowalsky S, Feist M, Kalinski P, Lu B, et al. Oncolytic immunotherapy: conceptual evolution, current strategies, and future perspectives. Front Immunol. 2017;8:555.
Article PubMed PubMed Central Google Scholar
Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20:160–77.
Menotti L, Avitabile E, Gatta V, Malatesta P, Petrovic B, Campadelli-Fiume G. HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic viruses. Viruses. 2018;10:352.
Article PubMed PubMed Central Google Scholar
Froechlich G, Gentile C, Infante L, Caiazza C, Pagano P, Scatigna S, et al. Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing. Int J Mol Sci. 2021;22:477.
Article CAS PubMed PubMed Central Google Scholar
Sasso E, Froechlich G, Cotugno G, D’Alise AM, Gentile C, Bignone V, et al. Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Sci Rep. 2020;10:4307.
Article CAS PubMed PubMed Central Google Scholar
Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Mol Ther. 2015;23:99–107.
Article CAS PubMed Google Scholar
Tripodi L, Feola S, Granata I, Whalley T, Passariello M, Capasso C, et al. Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma. iScience. 2023;26:107668.
Article CAS PubMed PubMed Central Google Scholar
de Graaf JF, de Vor L, Fouchier RAM, van den Hoogen BG. Armed oncolytic viruses: a kick-start for anti-tumor immunity. Cytokine Growth Factor Rev. 2018;41:28–39.
Article PubMed PubMed Central Google Scholar
Sasso E, D’Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol. 2020;50:101430.
Article CAS PubMed Google Scholar
Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020;8:e001486.
Article PubMed PubMed Central Google Scholar
Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641.
De Lucia M, Cotugno G, Bignone V, Garzia I, Nocchi L, Langone F, et al. Retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment. Mol Ther Oncolytics. 2020;19:253–64.
Article PubMed PubMed Central Google Scholar
Rivadeneira DB, DePeaux K, Wang Y, Kulkarni A, Tabib T, Menk AV, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity. 2019;51:548–60.e544.
Article CAS PubMed PubMed Central Google Scholar
Vetrei C, Passariello M, Froechlich G, Rapuano Lembo R, Sasso E, et al. Novel combinations of human immunomodulatory mabs lacking cardiotoxic effects for therapy of TNBC. Cancers. 2021;14:121.
Article PubMed PubMed Central Google Scholar
Baruah P, Lee M, Odutoye T, Williamson P, Hyde N, Kaski JC, et al. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology. 2012;217:669–75.
Article CAS PubMed Google Scholar
Kuss I, Donnenberg AD, Gooding W, Whi
留言 (0)